Cordlife (SGX:P8A) secured a one-year renewal of its cord blood banking service license, according to a Wednesday filing with the Singapore Exchange.
The company also received a two-year renewal for its human tissue banking service license from Jan. 14 to Jan. 13, 2028.
Under the conditions of the renewal of the two licenses, the company cannot collect, test, process and store CBUs from infant donors and is also required to replace its clinical governance officer and hire a suitable replacement.
Meanwhile, the company is also required to retrain its laboratory personnel.
Shares of the company surged nearly 19% in Wednesday trading.